(Q34666788)

3 August 2017

1 reference

title

Current medical treatment of glioblastoma (English)

1 reference

3 August 2017

Vyshak Alva Venur

1

1 reference

3 August 2017

David M Peereboom

series ordinal

2

1 reference

3 August 2017

Manmeet S Ahluwalia

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2015

1 reference

Cancer Treatment and Research

3 August 2017

published in

1 reference

3 August 2017

volume

163

1 reference

3 August 2017

page(s)

103-115

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

MGMT gene silencing and benefit from temozolomide in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

The potential role and application of PARP inhibitors in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Molecular mechanisms and clinical applications of angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Progress on antiangiogenic therapy for patients with malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

The WHO classification of tumors of the nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Malignant gliomas in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Therapeutic targeting of VEGF in the treatment of glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

A randomized trial of bevacizumab for newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

PCV chemotherapy for recurrent glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Bevacizumab and daily temozolomide for recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of gefitinib in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12048-5_7

10.1007/978-3-319-12048-5_7

31 March 2020

Identifiers

DOI

1 reference

3 August 2017

1 reference